Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial
- 11 February 2023
- journal article
- letter
- Published by Elsevier in Diabetes & Metabolism
- Vol. 49 (2) , 101433
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptideDiabetologia, 2019
- Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized TrialDiabetes Care, 2016
- Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 WeeksDiabetes Care, 2016
- Incretin-Modulated Beta Cell Energetics in Intact Islets of LangerhansMolecular Endocrinology, 2014
- The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cellsDiabetologia, 2013
- Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist StudyDiabetes, 2010